A Case of Locally Advanced Pancreatic Cancer Successfully Resected after 14 Months Therapy with Gemcitabine and Meriva®

Soldà, Caterina; Bardini, Romeo; Zingales, Francesca; Pastorelli, Davide

doi:10.18052/www.scipress.com/IJPPE.2.1

IJPPE > IJPPE Volume 2 > A Case of Locally Advanced Pancreatic Cancer...

< Back to Volume

A Case of Locally Advanced Pancreatic Cancer Successfully Resected after 14 Months Therapy with Gemcitabine and Meriva^®

Full Text PDF

Abstract:

Pancreatic cancer (PC) is one of the leading cause of cancer death. Neoadjuvant therapy has been progressively used in the context of locally advanced/unresectable disease improve patients’ outcome. New drugs combination are associated with increased response rate but at the expense of higher toxicities. We presented a case of a patient with locally advanced disease treated who could undergo surgery after 14 cycles of therapy with gemcitabine and curcumin conjugated with phospholipids (Meriva^®). Treatment was well tolerated without severe toxicities or impairment of quality of life. The patient is disease free at 9 month from surgery and 28 months from initial diagnosis and he still is in good clinical conditions. The combination of gemcitabine and Meriva® was effective in allowing radical surgery in a patient with locally advanced PC. Moreover, this results was obtained with minimally toxic regimen.

Info:

Periodical:

International Journal of Pharmacology, Phytochemistry and Ethnomedicine (Volume 2)

Pages:

1-4

DOI:

https://doi.org/10.18052/www.scipress.com/IJPPE.2.1

Citation:

C. Soldà et al., "A Case of Locally Advanced Pancreatic Cancer Successfully Resected after 14 Months Therapy with Gemcitabine and Meriva^®", International Journal of Pharmacology, Phytochemistry and Ethnomedicine, Vol. 2, pp. 1-4, 2016

Online since:

May 2016

Authors:

Caterina Soldà, Romeo Bardini, Francesca Zingales, Davide Pastorelli

Keywords:

Curcumin, Gemcitabine, Locally Advanced, Neoadjuvant, Pancreatic Cancer

Export:

RIS, BibTeX, Text

Distribution:

Open Access

This work is licensed under a
Creative Commons Attribution 4.0 International License

References:

[1] M. Malvezzi, P. Bertuccio, F. Levi, C. La Vecchia, E. Negri. European cancer mortality predictions for the year 2013. Ann Oncol. 24 (2013) 792-800.

DOI: https://doi.org/10.1093/annonc/mdt010

[2] G. Barugola, S. Partelli, S. Marcucci, N. Sartori, P. Capelli, C. Bassi, P. Pederzoli, M. Falconi. Resectable pancreatic cancer: who really benefits from resection? Ann Surg Oncol. 16 (2009) 3316-3322.

DOI: https://doi.org/10.1245/s10434-009-0670-7

[3] G.R. Varadhachary, E.P. Tamm, J.L. Abbruzzese, H.Q. Xiong, C.H. Crane, H. Wang, J.E. Lee, P.W. Pisters, D.B. Evans, R.A. Wolff. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 13 (2006).

DOI: https://doi.org/10.1245/aso.2006.08.011

[4] M. Glanemann, B. Shi, F. Liang, X.G. Sun, M. Bahra, D. Jacob, U. Neumann, P. Neuhaus. Surgical strategies for treatment of malignant pancreatic tumors: extended, standard or local surgery? World J Surg Oncol 6 (2008) 123.

DOI: https://doi.org/10.1186/1477-7819-6-123

[5] J.M. Laurence, P.D. Tran, K. Morarji, G.D. Eslick, V.W. Lam, C. Sandroussi. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg. 15 (2011).

DOI: https://doi.org/10.1007/s11605-011-1659-7

[6] A. Andriulli, V. Festa, E. Botteri, M.R. Valvano, M. Koch, C. Bassi, P. Maisonneuve, P.D. Sebastiano. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol. 19 (2012).

DOI: https://doi.org/10.1245/s10434-011-2110-8

[7] A. Shehzad, F. Wahid, Y.S. Lee. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. ArchPharm (Weinheim). 343 (2010) 489-499.

DOI: https://doi.org/10.1002/ardp.200900319

[8] T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud, Y. Bécouarn, A. Adenis, J.L. Raoul, S. Gourgou-Bourgade, C. de la Fouchardière, J. Bennouna, J.B. Bachet, F. Khemissa-Akouz, D. Péré-Vergé, C. Delbaldo, E. Assenat, B. Chauffert, P. Michel, C. Montoto-Grillot, M. Ducreux; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364 (2011).

DOI: https://doi.org/10.1056/nejmoa1011923

[9] D.D. Von Hoff, T. Ervin, F.P. Arena, E.G. Chiorean, J. Infante, M. Moore, T. Seay, S.A. Tjulandin, W.W. Ma, M.N. Saleh, M. Harris, M. Reni, S. Dowden, D. Laheru, N. Bahary, R.K. Ramanathan, J. Tabernero, M. Hidalgo, D. Goldstein, E. Van Cutsem, X. Wei, J. Iglesias, M.F. Renschler. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369 (2013).

DOI: https://doi.org/10.1056/nejmoa1304369

[10] F. Petrelli, A. Coinu, K. Borgonovo, M. Cabiddu, M. Ghilardi, V. Lonati, E. Aitini, S. Barni; Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD). FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas. 44 (2015).

DOI: https://doi.org/10.1097/mpa.0000000000000314

[11] C. Soldà, R. Bardini, C. Sperti, G. Da Dalt, M. Gion, P. Fiduccia, F. Ursini, C. Aliberti, D. Pastorelli. Phase II study of gemcitabine and curcumin as first line treatment for locally advanced or metastatic pancreatic cancer: preliminary data Ann Oncol 26 (suppl 4) (2015).

DOI: https://doi.org/10.1093/annonc/mdv344.41

Show More Hide

Cited By:

This article has no citations.